{"doi":"10.1002/pro.4843","title":"Molecular interactions between perlecan LG3 and the SARS‐CoV‐2 spike protein receptor binding domain","abstract":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global health crisis with significant clinical morbidity and mortality. While angiotensin-converting enzyme 2 (ACE2) is the primary receptor for viral entry, other cell surface and extracellular matrix proteins may also bind to the viral receptor binding domain (RBD) within the SARS-CoV-2 spike protein. Recent studies have implicated heparan sulfate proteoglycans, specifically perlecan LG3, in facilitating SARS-CoV-2 binding to ACE2. However, the role of perlecan LG3 in SARS-CoV-2 pathophysiology is not well understood. In this study, we investigated the binding interactions between the SARS-CoV-2 spike protein RBD and perlecan LG3 through molecular modeling simulations and surface plasmon resonance (SPR) experiments. Our results indicate stable binding between LG3 and SARS-CoV-2 spike protein RBD, which may potentially enhance RBD-ACE2 interactions. These findings shed light on the role of perlecan LG3 in SARS-CoV-2 infection and provide insight into SARS-CoV-2 pathophysiology and potential therapeutic strategy for COVID-19.","journal":"Protein Science","year":2023,"id":354445,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9538,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":763341,"name":"Md Lokman Hossen","orcid":"0000-0002-6059-3501","position":1,"is_corresponding":false},{"id":1102013,"name":"Grant Talkington","orcid":null,"position":2,"is_corresponding":false},{"id":1102014,"name":"Milla Volic","orcid":null,"position":3,"is_corresponding":false},{"id":1101611,"name":"Hugo Perez","orcid":"0009-0009-9011-344X","position":4,"is_corresponding":false},{"id":397586,"name":"Purushottam B. Tiwari","orcid":"0000-0002-3140-0723","position":5,"is_corresponding":false},{"id":291399,"name":"Prem P. Chapagain","orcid":"0000-0002-0999-4975","position":6,"is_corresponding":false},{"id":291402,"name":"Gregory Bix","orcid":"0000-0002-8969-9553","position":7,"is_corresponding":false},{"id":632547,"name":"Timothy E. Gressett","orcid":"0000-0003-3223-0188","position":0,"is_corresponding":true}],"reference_count":70,"raw_metadata":null,"created_at":"2026-07-19T01:13:06.959762Z","pmid":"37996967","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}